|
| related topics |
| {product, candidate, development} |
| {stock, price, share} |
| {stock, price, operating} |
| {control, financial, internal} |
| {property, intellectual, protect} |
| {loss, insurance, financial} |
| {debt, indebtedness, cash} |
| {regulation, government, change} |
| {regulation, change, law} |
| {competitive, industry, competition} |
| {cost, operation, labor} |
| {personnel, key, retain} |
|
|
Risks Related to Pro-Pharmaceuticals
We Are at an Early Stage of Development with Limited Operating History
We Have Incurred Net Losses to Date and Depend on Outside Capital
Our Product Candidates Will Be Based on Novel Unproven Technologies.
Our Drug Candidates are in Clinical Trials and Results Are Uncertain.
Our Product Candidates May Not Be Successfully Commercialized.
Our Lack of Operating Experience May Cause Us Difficulty in Managing Our Growth.
We Will Depend on Third Parties to Manufacture and Market Our Products.
We Depend on Key Individuals to Develop Our Products and Pursue Collaborations
We Are a Counterclaim Defendant in a Lawsuit Instituted by Dr. Platt
We Could Be Required to Make Substantial Cash Payments Upon an Event of Default Under Our Debentures.
We Cannot Take Certain Actions Without the Consent of the Debenture Holders.
Risks Related to the Drug Development Industry
We Will Need Regulatory Approvals to Commercialize Our Products.
Our Competitive Position Depends on Protection of Our Intellectual Property.
Products We Develop Could Be Subject to Infringement Claims Asserted by Others.
We Face Intense Competition in The Biotechnology and Pharmaceutical Industries.
Health Care Cost Containment Initiatives and the Growth of Managed Care May Limit Our Returns.
Our Insurance Coverage May Not Be Adequate In All Circumstances.
Risks Related to Our Stock
Stock Prices for Biopharmaceutical and Biotechnology Companies Are Volatile.
Large Sales Could Reduce the Trading Price of Our Common Stock.
Downward Pressure on Our Stock Price Could Result if Certain Stockholders Become Short-term Investors.
Four Principal Stockholders Own Enough Shares to Control The Company.
Changes in Laws, Regulations and Financial Accounting Standards May Affect Our Reported Results of Operations.
Full 10-K form ▸
|
|
| related documents |
| 873303--3/10/2009--AVI_BIOPHARMA_INC |
| 873303--3/16/2010--AVI_BIOPHARMA_INC |
| 352747--3/16/2007--UNIGENE_LABORATORIES_INC |
| 318306--5/1/2006--ACCESS_PHARMACEUTICALS_INC |
| 12239--4/4/2008--SPHERIX_INC |
| 1120438--3/15/2006--THIRD_WAVE_TECHNOLOGIES_INC_/WI |
| 1114872--3/29/2006--MILLENNIUM_CELL_INC |
| 908259--3/16/2010--OXIGENE_INC |
| 755806--3/1/2006--NEORX_CORP |
| 352747--3/16/2006--UNIGENE_LABORATORIES_INC |
| 708717--10/14/2008--ALFACELL_CORP |
| 1023024--3/31/2006--BIOSANTE_PHARMACEUTICALS_INC |
| 908259--3/14/2006--OXIGENE_INC |
| 805326--3/17/2008--EMISPHERE_TECHNOLOGIES_INC |
| 1123979--2/23/2007--SENOMYX_INC |
| 1123979--2/14/2008--SENOMYX_INC |
| 799698--4/3/2006--CYTRX_CORP |
| 1001233--3/16/2006--SANGAMO_BIOSCIENCES_INC |
| 1013238--3/31/2006--ARADIGM_CORP |
| 1017491--3/12/2008--NEXMED_INC |
| 1099215--7/31/2007--PROTALEX_INC |
| 849043--3/14/2006--NEUROGEN_CORP |
| 1110803--3/6/2006--ILLUMINA_INC |
| 1012270--3/16/2007--COLLAGENEX_PHARMACEUTICALS_INC |
| 1171012--3/12/2010--Uni-Pixel |
| 1120438--3/16/2007--THIRD_WAVE_TECHNOLOGIES_INC_/WI |
| 819050--2/25/2010--VICAL_INC |
| 819050--3/3/2009--VICAL_INC |
| 1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC |
| 819050--3/3/2008--VICAL_INC |
|